K5F Stock Overview
A clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Genenta Science S.p.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.62 |
| 52 Week High | US$5.30 |
| 52 Week Low | US$2.26 |
| Beta | 0.77 |
| 11 Month Change | -5.76% |
| 3 Month Change | -18.63% |
| 1 Year Change | -49.62% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -74.61% |
Recent News & Updates
Recent updates
Shareholder Returns
| K5F | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -3.7% | -0.5% | 0.8% |
| 1Y | -49.6% | -18.9% | 2.0% |
Return vs Industry: K5F underperformed the German Biotechs industry which returned -18.9% over the past year.
Return vs Market: K5F underperformed the German Market which returned 2% over the past year.
Price Volatility
| K5F volatility | |
|---|---|
| K5F Average Weekly Movement | 17.4% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: K5F's share price has been volatile over the past 3 months.
Volatility Over Time: K5F's weekly volatility has increased from 12% to 17% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 14 | Pierluigi Paracchi | www.genenta.com |
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma.
Genenta Science S.p.A. Fundamentals Summary
| K5F fundamental statistics | |
|---|---|
| Market cap | €52.93m |
| Earnings (TTM) | -€11.65m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-4.5x
P/E RatioIs K5F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| K5F income statement (TTM) | |
|---|---|
| Revenue | €0 |
| Cost of Revenue | €0 |
| Gross Profit | €0 |
| Other Expenses | €11.65m |
| Earnings | -€11.65m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.64 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did K5F perform over the long term?
See historical performance and comparison